Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company, today announced its participation in the upcoming H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference. The event is set to take place on March 28, 2024, involving a Fireside Chat with Edesa's CEO, Par Nijhawan, MD, and an H.C. Wainwright analyst. This discussion is scheduled to be available to registered attendees at approximately 7:00 am ET. Additionally, Edesa will host one-on-one meetings during the conference. Representatives and interested parties are encouraged to schedule a meeting through H.C. Wainwright contacts or directly with the company.